iRadimed (IRMD) Financials

$86.89 +1.62 (+1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$86.86 -0.03 (-0.04%)

As of 05:42 PM Eastern

Annual Income Statements for iRadimed

This table shows iRadimed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	7.53	7.21	0.50	6.30	9.63	1.37	9.33	13	17	19	22
Consolidated Net Income / (Loss)	7.53	7.21	0.50	6.30	9.63	1.37	9.33	13	17	19	22
Net Income / (Loss) Continuing Operations	7.53	7.21	0.50	6.30	9.63	1.37	9.33	13	17	19	22
Total Pre-Tax Income	12	11	1.40	6.20	9.04	-0.62	9.84	16	22	24	28
Total Operating Income	12	11	1.29	6.00	8.65	-0.76	9.82	16	20	22	26
Total Gross Profit	26	26	18	23	30	24	32	41	50	56	64
Total Revenue	32	32	23	30	39	32	42	53	66	73	84
Operating Revenue	32	32	23	30	39	32	42	53	66	73	84
Total Cost of Revenue	5.84	6.15	5.57	7.21	8.82	8.14	9.76	12	15	17	19
Operating Cost of Revenue	5.84	6.15	5.57	7.21	8.82	8.14	9.76	12	15	17	19
Total Operating Expenses	14	15	16	17	21	24	22	26	30	34	38
Selling, General & Admin Expense	7.77	8.80	9.00	8.71	10	12	9.77	11	15	16	18
Marketing Expense	4.71	5.28	5.50	7.00	9.17	10	11	13	12	16	17
Research & Development Expense	1.76	1.35	1.72	1.52	1.43	1.90	1.91	2.28	2.86	2.83	2.98
Total Other Income / (Expense), net	0.12	0.03	0.11	0.19	0.40	0.14	0.02	0.55	1.70	2.31	2.21
Other Income / (Expense), net	0.12	0.03	0.11	0.19	0.40	0.14	0.02	0.55	1.70	2.31	2.21
Income Tax Expense	4.10	3.74	0.90	-0.11	-0.59	-1.99	0.51	3.35	4.55	5.04	5.88
Basic Earnings per Share	$0.68	$0.67	$0.05	$0.59	$0.85	$0.11	$0.76	$1.02	$1.36	$1.52	$1.77
Weighted Average Basic Shares Outstanding	11.00M	10.82M	10.64M	10.76M	11.28M	12.12M	12.35M	12.56M	12.60M	12.67M	12.72M
Diluted Earnings per Share	$0.60	$0.60	$0.04	$0.52	$0.78	$0.11	$0.74	$1.02	$1.35	$1.50	$1.75
Weighted Average Diluted Shares Outstanding	12.56M	11.99M	11.72M	12.11M	12.28M	12.44M	12.59M	12.64M	12.72M	12.78M	12.85M
Weighted Average Basic & Diluted Shares Outstanding	11.10M	10.80M	10M	11.00M	11.92M	12.31M	12.56M	12.59M	12.66M	12.72M	12.78M

This table shows iRadimed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	5.07	4.54	4.14	4.90	5.05	5.15	4.69	5.77	5.58	6.44	5.82
Consolidated Net Income / (Loss)	5.07	4.54	4.14	4.90	5.05	5.15	4.69	5.77	5.58	6.44	5.82
Net Income / (Loss) Continuing Operations	5.07	4.54	4.14	4.90	5.05	5.15	4.69	5.77	5.58	6.44	5.82
Total Pre-Tax Income	6.41	5.68	5.24	6.27	6.42	6.34	5.95	7.33	7.30	7.79	7.77
Total Operating Income	5.91	5.16	4.75	5.63	5.79	5.80	5.43	6.79	6.83	7.09	7.24
Total Gross Profit	13	13	13	14	14	15	15	16	16	17	17
Total Revenue	17	17	18	18	18	19	20	20	21	23	22
Operating Revenue	17	17	18	18	18	19	20	20	21	23	22
Total Cost of Revenue	3.67	4.04	4.21	3.92	4.13	4.63	4.67	4.45	4.71	5.66	5.17
Operating Cost of Revenue	3.67	4.04	4.21	3.92	4.13	4.63	4.67	4.45	4.71	5.66	5.17
Total Operating Expenses	6.93	8.25	8.64	8.38	8.40	8.96	9.41	9.17	9.66	9.94	9.58
Selling, General & Admin Expense	3.62	4.27	3.99	4.10	3.97	3.87	4.61	4.28	4.36	4.54	4.57
Marketing Expense	2.86	5.54	3.83	3.48	3.80	7.52	4.18	4.01	4.63	4.60	4.05
Research & Development Expense	0.45	-1.56	0.82	0.80	0.64	-2.44	0.62	0.88	0.67	0.80	0.96
Total Other Income / (Expense), net	0.50	0.52	0.50	0.64	0.63	0.54	0.51	0.54	0.46	0.70	0.53
Other Income / (Expense), net	0.50	0.52	0.50	0.64	0.63	0.54	0.51	0.54	0.46	0.70	0.53
Income Tax Expense	1.34	1.14	1.11	1.37	1.37	1.20	1.26	1.55	1.72	1.35	1.95
Basic Earnings per Share	$0.40	$0.36	$0.33	$0.39	$0.40	$0.40	$0.37	$0.45	$0.44	$0.51	$0.46
Weighted Average Basic Shares Outstanding	12.60M	12.60M	12.66M	12.66M	12.67M	12.67M	12.71M	12.72M	12.72M	12.72M	12.78M
Diluted Earnings per Share	$0.40	$0.35	$0.32	$0.38	$0.40	$0.40	$0.37	$0.45	$0.43	$0.50	$0.45
Weighted Average Diluted Shares Outstanding	12.74M	12.72M	12.75M	12.76M	12.78M	12.78M	12.83M	12.84M	12.86M	12.85M	12.87M
Weighted Average Basic & Diluted Shares Outstanding	12.61M	12.66M	12.66M	12.67M	12.67M	12.72M	12.72M	12.72M	12.72M	12.78M	12.78M

This table details how cash moves in and out of iRadimed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	9.91	-1.65	0.49	9.82	15	6.59	12	-4.04	-8.20	2.47	-1.08
Net Cash From Operating Activities	7.65	9.41	3.42	7.38	10	5.82	11	10	13	26	25
Net Cash From Continuing Operating Activities	7.65	9.41	3.42	7.38	10	5.82	11	10	13	26	25
Net Income / (Loss) Continuing Operations	7.53	7.21	0.50	6.30	9.63	1.37	9.33	13	17	19	22
Consolidated Net Income / (Loss)	7.53	7.21	0.50	6.30	9.63	1.37	9.33	13	17	19	22
Depreciation Expense	0.81	0.96	1.31	1.11	1.24	1.34	1.41	0.67	0.77	0.82	1.17
Non-Cash Adjustments To Reconcile Net Income	1.34	2.04	2.75	1.93	1.93	3.90	1.62	1.59	2.61	2.52	2.95
Changes in Operating Assets and Liabilities, net	-2.03	-0.80	-1.14	-1.97	-2.57	-0.79	-1.07	-5.02	-7.11	3.05	-1.64
Net Cash From Investing Activities	-0.06	-1.94	-1.02	1.52	3.20	0.25	0.65	-1.37	-8.01	-8.82	-8.42
Net Cash From Continuing Investing Activities	-0.06	-1.94	-1.02	1.52	3.20	0.25	0.65	-1.37	-8.01	-8.82	-8.42
Purchase of Property, Plant & Equipment	-0.31	-1.52	-0.82	-0.26	-0.49	-0.64	-0.74	-1.87	-8.01	-8.82	-8.42
Net Cash From Financing Activities	2.33	-9.12	-1.90	0.93	2.02	0.52	0.02	-13	-14	-14	-18
Net Cash From Continuing Financing Activities	2.33	-9.12	-1.90	0.93	2.02	0.52	0.02	-13	-14	-14	-18
Payment of Dividends	-	-	-	-	-	-	0.00	-13	-13	-14	-15
Other Financing Activities, net	1.73	0.60	-0.16	0.93	-0.47	-1.21	0.02	-0.15	-0.43	-0.66	-2.56
Cash Income Taxes Paid	2.70	3.39	1.21	1.38	0.01	0.00	0.97	1.71	5.35	6.51	3.92

This table details how cash moves in and out of iRadimed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	0.92	3.02	-4.64	3.41	3.19	0.51	-1.90	2.66	3.53	-5.37	5.22
Net Cash From Operating Activities	1.39	3.91	3.88	6.64	9.12	5.99	4.29	7.75	6.99	5.92	8.29
Net Cash From Continuing Operating Activities	1.39	3.91	3.88	6.64	9.03	6.08	4.29	7.75	6.99	5.92	8.29
Net Income / (Loss) Continuing Operations	5.07	4.54	4.14	4.90	5.05	5.15	4.69	5.77	5.58	6.44	5.82
Consolidated Net Income / (Loss)	5.07	4.54	4.14	4.90	5.05	5.15	4.69	5.77	5.58	6.44	5.82
Depreciation Expense	0.19	0.21	0.23	0.20	0.20	0.19	0.19	0.21	0.38	0.38	0.46
Non-Cash Adjustments To Reconcile Net Income	0.57	0.59	0.63	0.74	0.02	1.13	0.77	0.76	0.68	0.73	0.74
Changes in Operating Assets and Liabilities, net	-4.43	-1.42	-1.11	0.80	3.75	-0.40	-1.36	1.00	0.34	-1.63	1.28
Net Cash From Investing Activities	-0.44	-0.63	-0.48	-1.27	-4.01	-3.06	-3.92	-2.82	-1.26	-0.42	-0.47
Net Cash From Continuing Investing Activities	-0.44	-0.63	-0.48	-1.27	-4.01	-3.06	-3.92	-2.82	-1.26	-0.42	-0.47
Purchase of Property, Plant & Equipment	-0.44	-0.63	-0.48	-1.27	-4.01	-3.06	-3.70	-2.82	-1.26	-0.42	-0.40
Acquisitions	-	-	-	-	-	-	-0.22	-	-	-	-0.07
Net Cash From Financing Activities	-0.03	-0.26	-8.04	-1.96	-1.92	-2.42	-2.28	-2.26	-2.19	-11	-2.61
Net Cash From Continuing Financing Activities	-0.03	-0.26	-8.04	-1.96	-1.92	-2.42	-2.28	-2.26	-2.19	-11	-2.61
Payment of Dividends	-	-	-7.98	-1.90	-1.90	-1.90	-2.16	-2.16	-2.16	-8.55	-2.56
Other Financing Activities, net	-0.03	-0.26	-0.06	-0.06	-0.02	-0.52	-0.12	-0.10	-0.03	-2.32	-0.05
Cash Income Taxes Paid	1.38	1.22	0.19	2.82	1.45	2.06	0.01	2.34	0.15	1.42	0.01

This table presents iRadimed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	35	37	39	48	67	71	83	86	92	98	109
Total Current Assets	34	34	35	45	59	64	76	77	76	75	81
Cash & Equivalents	19	18	18	28	43	50	62	58	50	52	51
Accounts Receivable	3.86	3.78	3.78	4.21	7.29	4.57	5.14	13	12	11	14
Inventories, net	2.38	3.89	4.21	4.06	3.64	3.93	4.30	5.37	13	10	12
Prepaid Expenses	0.32	0.36	0.65	0.53	0.41	0.77	1.00	0.63	1.19	2.05	1.65
Current Deferred & Refundable Income Taxes	0.42	0.15	0.13	1.37	1.37	2.48	3.31	0.25	-	-	3.11
Plant, Property, & Equipment, net	0.91	1.46	1.87	1.87	2.05	2.12	2.07	2.40	9.29	17	24
Total Noncurrent Assets	0.39	1.88	2.04	2.03	5.71	5.21	4.57	5.62	6.87	6.27	3.72
Intangible Assets	0.19	0.92	0.89	0.83	0.86	0.96	1.12	2.07	2.52	3.10	3.38
Noncurrent Deferred & Refundable Income Taxes	0.09	0.79	0.95	1.09	1.66	1.27	0.77	0.70	2.12	2.82	0.09
Other Noncurrent Operating Assets	0.10	0.17	0.20	0.11	3.19	2.98	2.68	2.85	2.22	0.35	0.24
Total Liabilities & Shareholders' Equity	35	37	39	48	67	71	83	86	92	98	109
Total Liabilities	3.31	5.31	6.08	6.50	11	9.68	11	12	21	12	14
Total Current Liabilities	2.89	3.66	4.08	4.69	5.86	4.92	6.82	8.55	16	8.51	10
Accounts Payable	1.01	1.12	0.66	0.77	0.99	0.66	0.78	1.80	1.86	1.90	1.82
Accrued Expenses	0.03	0.04	0.06	0.07	0.08	0.09	0.11	0.09	0.12	0.12	0.14
Current Deferred Revenue	0.53	1.03	1.62	1.80	1.67	1.95	2.55	3.37	2.57	2.26	2.87
Current Deferred & Payable Income Tax Liabilities	-	0.19	0.01	-	-	-	-	0.00	0.25	0.00	1.81
Current Employee Benefit Liabilities	1.29	1.04	1.51	1.80	2.17	1.71	2.81	2.87	2.78	3.77	3.22
Other Taxes Payable	0.03	0.12	0.11	0.13	0.60	0.10	0.14	0.12	0.10	-	0.31
Total Noncurrent Liabilities	0.42	1.64	2.00	1.81	5.35	4.76	3.88	3.29	4.41	3.00	3.98
Noncurrent Deferred Revenue	0.42	1.64	2.00	1.81	2.63	2.31	1.68	1.38	2.79	2.99	3.98
Total Equity & Noncontrolling Interests	32	32	33	42	56	61	72	74	71	87	95
Total Preferred & Common Equity	32	32	33	42	56	61	72	74	71	87	95
Total Common Equity	32	32	33	42	56	61	72	74	71	87	95
Common Stock	19	12	13	15	19	24	25	26	28	30	30
Retained Earnings	13	20	20	27	36	38	47	47	43	57	64

This table presents iRadimed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	80	76	81	87	88	90	94	102	106	115	114
Total Current Assets	72	61	66	72	72	74	74	75	77	85	86
Cash & Equivalents	56	43	46	47	45	49	52	50	53	57	56
Accounts Receivable	11	12	11	13	13	12	10	13	11	14	13
Inventories, net	5.24	6.31	8.42	12	13	12	11	11	11	12	12
Prepaid Expenses	0.39	0.68	0.77	0.74	1.04	1.02	0.95	1.54	1.92	1.10	1.63
Current Deferred & Refundable Income Taxes	0.00	0.00	0.00	0.00	-	-	-	-	0.33	1.70	3.13
Plant, Property, & Equipment, net	2.29	8.64	8.72	8.89	9.45	10	14	20	23	24	24
Total Noncurrent Assets	5.38	5.68	6.62	6.59	6.68	5.90	5.80	6.21	6.14	6.01	3.74
Intangible Assets	1.88	2.21	2.35	2.46	2.67	2.75	2.89	3.26	3.37	3.37	3.29
Noncurrent Deferred & Refundable Income Taxes	0.99	0.62	1.77	1.80	1.88	2.59	2.46	2.69	2.56	2.42	0.23
Other Noncurrent Operating Assets	2.51	2.85	2.50	2.32	2.12	0.56	0.45	0.27	0.20	0.21	0.23
Total Liabilities & Shareholders' Equity	80	76	81	87	88	90	94	102	106	115	114
Total Liabilities	9.77	11	12	13	12	10	11	12	12	16	16
Total Current Liabilities	5.60	6.76	7.59	7.88	7.62	7.46	8.06	8.47	8.81	13	12
Accounts Payable	0.96	1.76	2.55	2.78	1.29	1.12	1.40	2.59	1.90	2.33	2.18
Accrued Expenses	0.10	0.10	0.11	0.11	0.12	0.12	0.12	0.12	0.12	0.14	0.14
Current Deferred Revenue	1.59	2.07	1.71	1.92	2.34	2.54	2.56	2.60	3.26	3.16	3.40
Current Deferred & Payable Income Tax Liabilities	-	0.49	-	-	0.93	0.00	0.00	0.58	-	2.80	3.90
Current Employee Benefit Liabilities	2.35	1.62	2.33	2.29	2.14	2.90	3.28	2.27	3.21	4.07	2.07
Other Taxes Payable	0.18	0.06	0.22	0.10	0.14	0.16	0.19	0.26	0.32	0.30	0.43
Total Noncurrent Liabilities	4.17	4.52	4.85	4.96	4.28	2.82	2.75	3.20	3.33	3.57	3.76
Noncurrent Deferred Revenue	2.18	2.59	3.01	3.23	2.76	2.82	2.75	3.20	3.33	3.57	3.76
Total Equity & Noncontrolling Interests	70	64	69	75	76	80	83	90	94	98	99
Total Preferred & Common Equity	70	64	69	75	76	80	83	90	94	98	99
Total Common Equity	70	64	69	75	76	80	83	90	94	98	99
Common Stock	26	27	27	28	29	29	30	31	31	32	31
Retained Earnings	44	37	42	47	47	50	54	59	63	66	67

This table displays calculated financial ratios and metrics derived from iRadimed's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	12,721,156.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	12,721,156.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	1.77
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	7.45	7.19	0.46	6.11	9.21	-0.53	9.31	12	16	17	21
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	22.19%	20.05%	21.90%
Earnings before Interest and Taxes (EBIT)	12	11	1.40	6.20	9.04	-0.62	9.84	16	22	24	28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	12	12	2.71	7.30	10	0.72	11	17	23	25	30
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	6.01	5.95	0.08	5.13	7.50	-0.66	9.04	6.35	1.92	12	12
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	4.96	6.21	6.59	7.57	9.27	9.41	9.67	16	30	35	43
Increase / (Decrease) in Invested Capital	1.44	1.25	0.38	0.98	1.71	0.13	0.27	6.04	14	4.95	8.87
Book Value per Share	$2.88	$2.98	$3.12	$3.84	$4.83	$5.00	$5.85	$5.86	$5.67	$6.85	$7.44
Tangible Book Value per Share	$2.87	$2.89	$3.04	$3.76	$4.76	$4.92	$5.76	$5.70	$5.47	$6.61	$7.17
Total Capital	32	32	33	42	56	61	72	74	71	87	95
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-27	-26	-26	-34	-46	-52	-63	-58	-50	-52	-51
Capital Expenditures (CapEx)	0.31	1.52	0.82	0.26	0.49	0.64	0.74	1.87	8.01	8.82	8.42
Debt-free, Cash-free Net Working Capital (DFCFNWC)	4.09	4.52	4.69	5.47	6.85	6.84	6.92	11	9.91	14	20
Debt-free Net Working Capital (DFNWC)	31	30	31	40	53	59	69	69	60	67	71
Net Working Capital (NWC)	31	30	31	40	53	59	69	69	60	67	71
Net Nonoperating Expense (NNE)	-0.08	-0.02	-0.04	-0.20	-0.42	-1.90	-0.02	-0.44	-1.35	-1.83	-1.75
Net Nonoperating Obligations (NNO)	-27	-26	-26	-34	-46	-52	-63	-58	-42	-52	-51
Total Depreciation and Amortization (D&A)	0.81	0.96	1.31	1.11	1.24	1.34	1.41	0.67	0.77	0.82	1.17
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.68	$0.67	$0.05	$0.59	$0.85	$0.11	$0.76	$1.02	$1.36	$1.52	$1.77
Adjusted Weighted Average Basic Shares Outstanding	11.00M	10.82M	10.64M	10.76M	11.28M	12.12M	12.35M	12.56M	12.60M	12.67M	12.72M
Adjusted Diluted Earnings per Share	$0.60	$0.60	$0.04	$0.52	$0.78	$0.11	$0.74	$1.02	$1.35	$1.50	$1.75
Adjusted Weighted Average Diluted Shares Outstanding	12.56M	11.99M	11.72M	12.11M	12.28M	12.44M	12.59M	12.64M	12.72M	12.78M	12.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	11.03M	10.74M	10.60M	11.00M	11.92M	12.31M	12.56M	12.59M	12.66M	12.72M	12.78M
Normalized Net Operating Profit after Tax (NOPAT)	7.45	7.19	0.90	4.20	6.05	-0.53	9.31	12	16	17	21
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from iRadimed's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	12,721,156.00	12,782,566.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	12,721,156.00	12,782,566.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	0.51	0.46
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	23.10%	17.42%	13.72%	11.15%	11.04%	11.10%	10.87%	13.84%	15.69%	-	12.65%
EBITDA Growth	41.20%	46.78%	20.68%	17.91%	0.26%	11.08%	12.25%	16.49%	16.11%	-	33.96%
EBIT Growth	51.23%	20.79%	20.55%	18.32%	0.15%	11.66%	13.39%	16.88%	13.70%	-	30.68%
NOPAT Growth	39.71%	24.09%	19.38%	12.36%	-2.46%	14.13%	14.32%	21.59%	14.66%	-	26.55%
Net Income Growth	47.86%	23.58%	21.45%	17.26%	-0.35%	13.37%	13.32%	17.81%	10.44%	-	24.13%
EPS Growth	48.15%	20.69%	18.52%	15.15%	0.00%	14.29%	15.63%	18.42%	7.50%	-	21.62%
Operating Cash Flow Growth	-64.64%	28.75%	-16.42%	88.93%	554.54%	53.02%	10.53%	16.69%	-23.36%	-	93.15%
Free Cash Flow Firm Growth	-296.70%	-260.61%	16.66%	35.47%	107.42%	97.49%	21.80%	-35.34%	-834.80%	-	167.54%
Invested Capital Growth	96.22%	88.61%	43.74%	34.35%	13.98%	16.71%	28.16%	32.66%	31.89%	-	6.08%
Revenue Q/Q Growth	2.32%	5.74%	0.84%	1.88%	2.21%	5.80%	0.63%	4.61%	3.88%	-	-3.14%
EBITDA Q/Q Growth	20.28%	-10.78%	-7.09%	18.26%	2.28%	-1.16%	-6.11%	22.72%	1.95%	-	0.65%
EBIT Q/Q Growth	20.95%	-11.34%	-7.71%	19.56%	2.38%	-1.15%	-6.29%	23.24%	-0.40%	-	-0.28%
NOPAT Q/Q Growth	19.26%	-11.71%	-9.14%	17.44%	3.53%	3.31%	-8.99%	24.91%	-2.37%	-	-7.61%
Net Income Q/Q Growth	21.23%	-10.41%	-8.88%	18.49%	3.03%	1.93%	-8.93%	23.18%	-3.42%	-	-9.69%
EPS Q/Q Growth	21.21%	-12.50%	-8.57%	18.75%	5.26%	0.00%	-7.50%	21.62%	-4.44%	-	-10.00%
Operating Cash Flow Q/Q Growth	-60.36%	180.93%	-0.75%	70.96%	37.32%	-34.32%	-28.31%	80.48%	-9.81%	-	39.97%
Free Cash Flow Firm Q/Q Growth	-62.60%	-9.19%	41.97%	37.36%	118.69%	-136.88%	-1,710.86%	-8.40%	-1.49%	-	199.83%
Invested Capital Q/Q Growth	20.05%	6.51%	4.59%	0.46%	1.85%	9.06%	14.86%	3.98%	1.26%	-	-3.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	77.78%	76.86%	76.07%	78.14%	77.44%	76.13%	76.08%	78.17%	77.80%	-	76.50%
EBITDA Margin	39.98%	33.73%	31.08%	36.08%	36.10%	33.73%	31.47%	36.92%	36.23%	-	37.42%
Operating Margin	35.78%	29.57%	26.98%	31.39%	31.59%	29.91%	27.84%	33.26%	32.23%	-	32.93%
EBIT Margin	38.83%	32.56%	29.80%	34.97%	35.02%	32.72%	30.47%	35.90%	34.42%	-	35.35%
Profit (Net Income) Margin	30.70%	26.01%	23.51%	27.34%	27.55%	26.54%	24.03%	28.29%	26.30%	-	26.47%
Tax Burden Percent	79.07%	79.90%	78.89%	78.18%	78.67%	81.12%	78.84%	78.80%	76.42%	-	74.89%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-	100.00%
Effective Tax Rate	20.93%	20.10%	21.11%	21.82%	21.33%	18.88%	21.16%	21.20%	23.58%	-	25.11%
Return on Invested Capital (ROIC)	84.83%	68.31%	54.83%	62.78%	59.53%	55.36%	46.65%	56.18%	53.93%	-	51.98%
ROIC Less NNEP Spread (ROIC-NNEP)	84.06%	67.47%	53.94%	61.72%	58.53%	54.42%	45.80%	55.34%	53.28%	-	51.23%
Return on Net Nonoperating Assets (RNNOA)	-59.60%	-46.39%	-33.75%	-39.17%	-36.47%	-32.33%	-26.31%	-32.30%	-31.72%	-	-28.99%
Return on Equity (ROE)	25.24%	21.92%	21.07%	23.61%	23.06%	23.02%	20.34%	23.88%	22.21%	-	22.99%
Cash Return on Invested Capital (CROIC)	6.67%	8.49%	26.72%	33.05%	43.45%	38.78%	26.05%	24.08%	25.70%	-	47.51%
Operating Return on Assets (OROA)	29.29%	24.03%	24.65%	28.35%	27.50%	25.16%	24.14%	28.38%	26.52%	-	28.22%
Return on Assets (ROA)	23.16%	19.20%	19.45%	22.17%	21.63%	20.41%	19.03%	22.37%	20.27%	-	21.14%
Return on Common Equity (ROCE)	25.24%	21.92%	21.07%	23.61%	23.06%	23.02%	20.34%	23.88%	22.21%	-	22.99%
Return on Equity Simple (ROE_SIMPLE)	21.90%	0.00%	23.55%	23.40%	22.33%	0.00%	21.97%	0.00%	0.00%	-	0.00%
Net Operating Profit after Tax (NOPAT)	4.67	4.12	3.75	4.40	4.55	4.71	4.28	5.35	5.22	5.87	5.42
NOPAT Margin	28.29%	23.62%	21.29%	24.54%	24.85%	24.27%	21.95%	26.21%	24.63%	-	24.66%
Net Nonoperating Expense Percent (NNEP)	0.78%	0.84%	0.89%	1.06%	1.01%	0.94%	0.85%	0.84%	0.66%	-	0.75%
Return On Investment Capital (ROIC_SIMPLE)	-	5.77%	-	-	-	5.42%	4.76%	5.67%	5.31%	6.20%	5.50%
Cost of Revenue to Revenue	22.22%	23.14%	23.93%	21.86%	22.56%	23.87%	23.92%	21.83%	22.20%	-	23.50%
SG&A Expenses to Revenue	21.90%	24.49%	22.68%	22.90%	21.65%	19.98%	23.63%	20.97%	20.54%	-	20.79%
R&D to Revenue	2.74%	-8.91%	21.75%	4.47%	3.49%	-12.56%	3.20%	4.30%	3.18%	-	4.35%
Operating Expenses to Revenue	42.00%	47.29%	49.09%	46.75%	45.85%	46.21%	48.24%	44.92%	45.56%	-	43.57%
Earnings before Interest and Taxes (EBIT)	6.41	5.68	5.24	6.27	6.42	6.34	5.95	7.33	7.30	7.79	7.77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	6.60	5.89	5.47	6.47	6.62	6.54	6.14	7.53	7.68	8.17	8.22
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.34	8.27	7.27	6.96	7.64	8.00	7.41	8.06	9.20	-	12.49
Price to Tangible Book Value (P/TBV)	7.60	8.58	7.53	7.21	7.91	8.30	7.69	8.36	9.53	-	12.92
Price to Revenue (P/Rev)	8.70	9.01	8.17	7.98	8.94	9.49	8.88	9.79	11.24	-	14.26
Price to Earnings (P/E)	33.54	34.37	30.87	29.75	34.21	36.13	33.73	36.80	42.71	-	52.11
Dividend Yield	2.42%	3.26%	3.50%	1.44%	1.55%	1.70%	1.18%	1.07%	0.93%	-	1.26%
Earnings Yield	2.98%	2.91%	3.24%	3.36%	2.92%	2.77%	2.97%	2.72%	2.34%	-	1.92%
Enterprise Value to Invested Capital (EV/IC)	18.00	18.26	16.39	16.25	18.46	18.58	15.53	17.12	20.28	-	27.86
Enterprise Value to Revenue (EV/Rev)	7.95	8.25	7.51	7.28	8.21	8.78	8.21	9.11	10.54	-	13.61
Enterprise Value to EBITDA (EV/EBITDA)	24.28	24.04	21.68	20.72	23.95	25.61	23.95	26.36	30.41	-	37.14
Enterprise Value to EBIT (EV/EBIT)	24.13	24.89	22.45	21.44	24.79	26.48	24.70	27.16	31.52	-	38.90
Enterprise Value to NOPAT (EV/NOPAT)	33.30	34.15	30.88	29.88	34.80	36.93	34.39	37.44	43.36	-	53.70
Enterprise Value to Operating Cash Flow (EV/OCF)	39.78	40.18	40.00	31.97	24.86	25.08	23.70	26.06	33.92	-	40.56
Enterprise Value to Free Cash Flow (EV/FCFF)	357.68	281.19	72.36	56.38	45.27	51.61	66.98	81.09	89.78	-	60.37
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Financial Leverage	-0.71	-0.69	-0.63	-0.63	-0.62	-0.59	-0.57	-0.58	-0.60	-	-0.57
Leverage Ratio	1.16	1.22	1.17	1.15	1.15	1.20	1.14	1.13	1.15	-	1.15
Compound Leverage Factor	1.16	1.22	1.17	1.15	1.15	1.20	1.14	1.13	1.15	-	1.15
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Altman Z-Score	28.19	19.45	30.51	35.04	37.97	38.82	36.83	40.11	35.64	-	49.09
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.13	4.65	9.44	9.87	9.21	8.84	8.87	8.78	6.64	-	7.13
Quick Ratio	7.55	3.80	7.64	8.11	7.70	7.38	7.44	7.25	5.50	-	5.76
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-8.97	-9.80	-5.69	-3.56	0.67	-0.25	-4.45	-4.82	-4.89	-3.01	3.00
Operating Cash Flow to CapEx	317.22%	618.27%	811.01%	522.81%	227.24%	195.87%	109.57%	274.33%	552.89%	-	2,057.07%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.75	0.74	0.83	0.81	0.79	0.77	0.79	0.79	0.77	-	0.80
Accounts Receivable Turnover	5.37	5.14	5.51	6.03	6.16	6.43	5.84	6.79	6.65	-	6.61
Inventory Turnover	1.77	1.69	1.67	1.55	1.42	1.45	1.49	1.54	1.61	-	1.78
Fixed Asset Turnover	11.27	11.22	7.48	7.24	6.19	5.61	5.04	4.65	4.24	-	3.87
Accounts Payable Turnover	8.01	8.43	10.43	8.62	7.79	9.00	8.95	11.84	9.89	-	8.38
Days Sales Outstanding (DSO)	67.91	70.98	66.22	60.50	59.25	56.76	62.49	53.77	54.91	-	55.25
Days Inventory Outstanding (DIO)	205.64	215.51	218.72	236.09	256.56	250.90	244.59	237.47	227.27	-	204.89
Days Payable Outstanding (DPO)	45.57	43.32	35.00	42.33	46.83	40.55	40.77	30.84	36.92	-	43.57
Cash Conversion Cycle (CCC)	227.99	243.17	249.94	254.26	268.98	267.11	266.31	260.40	245.26	-	216.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	28	30	31	31	32	35	40	41	42	43	42
Invested Capital Turnover	3.00	2.89	2.58	2.56	2.40	2.28	2.13	2.14	2.19	-	2.11
Increase / (Decrease) in Invested Capital	14	14	9.43	7.96	3.89	4.95	8.73	10	10	8.87	2.42
Enterprise Value (EV)	501	541	508	506	585	643	617	707	848	-	1,174
Market Capitalization	548	591	553	555	637	695	667	760	905	-	1,230
Book Value per Share	$5.92	$5.67	$6.01	$6.29	$6.59	$6.85	$7.08	$7.42	$7.74	$7.44	$7.71
Tangible Book Value per Share	$5.72	$5.47	$5.80	$6.07	$6.36	$6.61	$6.83	$7.15	$7.47	$7.17	$7.45
Total Capital	75	71	76	80	83	87	90	94	98	95	99
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-47	-50	-45	-49	-52	-52	-50	-53	-57	-51	-56
Capital Expenditures (CapEx)	0.44	0.63	0.48	1.27	4.01	3.06	3.92	2.82	1.26	0.42	0.40
Debt-free, Cash-free Net Working Capital (DFCFNWC)	17	9.91	19	18	15	14	16	16	16	20	18
Debt-free Net Working Capital (DFNWC)	64	60	64	66	66	67	67	69	72	71	74
Net Working Capital (NWC)	64	60	64	66	66	67	67	69	72	71	74
Net Nonoperating Expense (NNE)	-0.40	-0.42	-0.39	-0.50	-0.50	-0.44	-0.41	-0.42	-0.35	-0.58	-0.40
Net Nonoperating Obligations (NNO)	-47	-42	-45	-49	-52	-52	-50	-53	-57	-51	-56
Total Depreciation and Amortization (D&A)	0.19	0.21	0.23	0.20	0.20	0.19	0.19	0.21	0.38	0.38	0.46
Debt-free, Cash-free Net Working Capital to Revenue	27.48%	15.12%	28.28%	25.31%	20.34%	19.79%	21.73%	20.05%	19.37%	-	20.78%
Debt-free Net Working Capital to Revenue	101.71%	91.02%	94.95%	95.16%	92.87%	91.11%	88.70%	88.31%	89.58%	-	86.12%
Net Working Capital to Revenue	101.71%	91.02%	94.95%	95.16%	92.87%	91.11%	88.70%	88.31%	89.58%	-	86.12%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.40	$0.36	$0.33	$0.39	$0.40	$0.40	$0.37	$0.45	$0.44	$0.51	$0.46
Adjusted Weighted Average Basic Shares Outstanding	12.60M	12.60M	12.66M	12.66M	12.67M	12.67M	12.71M	12.72M	12.72M	12.72M	12.78M
Adjusted Diluted Earnings per Share	$0.40	$0.35	$0.32	$0.38	$0.40	$0.40	$0.37	$0.45	$0.43	$0.50	$0.45
Adjusted Weighted Average Diluted Shares Outstanding	12.74M	12.72M	12.75M	12.76M	12.78M	12.78M	12.83M	12.84M	12.86M	12.85M	12.87M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.61M	12.66M	12.66M	12.67M	12.67M	12.72M	12.72M	12.72M	12.72M	12.78M	12.78M
Normalized Net Operating Profit after Tax (NOPAT)	4.67	4.12	3.75	4.40	4.55	4.71	4.28	5.35	5.22	5.87	5.42
Normalized NOPAT Margin	28.29%	23.62%	21.29%	24.54%	24.85%	24.27%	21.95%	26.21%	24.63%	-	24.66%
Pre Tax Income Margin	38.83%	32.56%	29.80%	34.97%	35.02%	32.72%	30.47%	35.90%	34.42%	-	35.35%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	80.99%	76.91%	44.50%	52.97%	63.22%	71.11%	39.74%	39.33%	39.59%	-	65.37%
Augmented Payout Ratio	80.99%	76.91%	44.50%	52.97%	63.22%	71.11%	39.74%	39.33%	39.59%	-	65.37%

Financials Breakdown Chart

Key Financial Trends

IRadimed Corp (IRMD) has shown a generally positive trajectory over the last four years, with a growing revenue base, stable high gross margins, improving operating profitability, and solid balance sheet liquidity. Here are the most meaningful takeaways based on quarterly data from 2022 through 2025.

Revenue has trended higher over the period, with Q4 2025 revenue around $22.69M versus approximately $14.86M in Q4 2022, indicating a meaningful top-line expansion.
Gross margin has remained strong and stable in the mid-70% range (about 75%–76%), signaling solid pricing and cost control across years.
Operating margin has remained solid, with quarterly operating income around 30%+ of revenue (Q4 2025 operating income about $7.09M on $22.69M revenue).
Net income and EPS have trended higher in later years, with Q4 2025 net income attributable to common shareholders around $6.44M and diluted EPS near $0.50, compared with prior years’ lower levels.
Cash flow from operations has been consistently positive and sizable (for example, about $5.92M in Q4 2025 and $7.75M in Q3 2025), supporting ongoing liquidity and flexibility.
The balance sheet shows a strong equity base and relatively modest liabilities, with Total Assets around $100–115M and Total Liabilities well below Total Equity in recent periods, indicating solid solvency.
Liquidity remains healthy, with cash balances in the mid-to-high $50M range across 2024–2025 and a robust current asset base versus current liabilities (implied healthy liquidity ratios).
Dividend payments (and related financing activity) provide shareholder value but reduce cash, making dividends a neutral factor for growth-oriented investors.
Ongoing capital expenditures are present (PPE purchases), reflecting reinvestment in capacity and operations; this is a neutral factor for near-term cash flow but supports potential long-term growth.
Near-term cash balance can be pressured by financing activities, as seen in quarterly nets from financing activities and occasional negative net changes in cash (e.g., Q4 2025 net change in cash of about -$5.37M driven by financing outflows).

05/14/26 06:04 PM ETAI Generated. May Contain Errors.

iRadimed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, iRadimed's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

iRadimed's net income appears to be on an upward trend, with a most recent value of $22.48 million in 2025, rising from $7.53 million in 2015. The previous period was $19.23 million in 2024. View iRadimed's forecast to see where analysts expect iRadimed to go next.

iRadimed's total operating income in 2025 was $26.15 million, based on the following breakdown:

Total Gross Profit: $64.32 million
Total Operating Expenses: $38.18 million

Over the last 10 years, iRadimed's total revenue changed from $31.59 million in 2015 to $83.81 million in 2025, a change of 165.3%.

iRadimed's total liabilities were at $14.16 million at the end of 2025, a 23.0% increase from 2024, and a 327.6% increase since 2015.

In the past 10 years, iRadimed's cash and equivalents has ranged from $17.71 million in 2016 to $62.00 million in 2021, and is currently $51.16 million as of their latest financial filing in 2025.

Over the last 10 years, iRadimed's book value per share changed from 2.88 in 2015 to 7.44 in 2025, a change of 157.8%.

Related Companies

Financial statements for NASDAQ:IRMD last updated on 5/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iRadimed (IRMD) Financials

Financials Breakdown Chart

Key Financial Trends

iRadimed Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iRadimed (IRMD) Financials

Annual Income Statements for iRadimed

Quarterly Income Statements for iRadimed

Annual Cash Flow Statements for iRadimed

Quarterly Cash Flow Statements for iRadimed

Annual Balance Sheets for iRadimed

Quarterly Balance Sheets for iRadimed

Annual Metrics And Ratios for iRadimed

Quarterly Metrics And Ratios for iRadimed

Financials Breakdown Chart

Key Financial Trends

iRadimed Financials - Frequently Asked Questions

When does iRadimed's fiscal year end?

How has iRadimed's net income changed over the last 10 years?

What is iRadimed's operating income?

How has iRadimed's revenue changed over the last 10 years?

How much debt does iRadimed have?

How much cash does iRadimed have?

How has iRadimed's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools